- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05003466
Study of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 3 to 17 Years(COVID-19)
11. august 2021 oppdatert av: Shenzhen Kangtai Biological Products Co., LTD
A Randomized, Double-blind, Placebo-controlled Phase Ⅱ Clinical Study to Evaluate the Safety and Immunogenicity of Inactivated SARS-CoV-2 Vaccine (Vero Cells) in Healthy Population Aged 3 to 17 Years
This study is a randomized, double-blinded, and placebo controlled phase Ⅱ clinical trial of the SARS-CoV-2 inactivated vaccine to evaluate the safety and immunogenicity of the experimental vaccine in healthy population aged 3 to 17 years.
Studieoversikt
Status
Har ikke rekruttert ennå
Forhold
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Forventet)
480
Fase
- Fase 2
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiekontakt
- Navn: Guifan Li, M.S
- Telefonnummer: +861059613591
- E-post: liguifan@biominhai.com
Studiesteder
-
-
Hunan
-
Changsha, Hunan, Kina, 410005
- Hunan Provincial Center for Diseases Control and Prevention
-
Ta kontakt med:
- Tao Huang
- Telefonnummer: +8673184305935
- E-post: ymlc01@hncdc.com
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
3 år til 17 år (Barn)
Tar imot friske frivillige
Ja
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Healthy residents aged 3 to 17 years at the time of consent
- Subjects and/or their guardian agree to sign the informed consent forms voluntarily.
- Be able to comply with study requirements/procedures.
- Axillary temperature ≤ 37.0℃
Exclusion Criteria:
- Within 14 days before vaccination, subjects have been abroad and to villages/communities experienced COVID-19 epidemics, and in contact with COVID-19 cases or suspected cases. Subjects are under isolation observation, or living in the villages/communities with COVID-19 cases or suspected cases;
- Confirmed cases, suspected cases or asymptomatic cases with COVID-19 (refer to Information System of China Disease Prevention and Control);
- Subjects with history of SARS virus infection by self-reported;
- Positive in throat swab through RT-PCR;
- History of vaccination of various COVID-19 vaccines or positive in SARS-CoV-2 antibody test;
- Positive urine pregnancy test for females with menarche
- History of severe allergic reactions (such as acute anaphylaxis, urticaria, skin eczema, dyspnea, angioneurotic edema or abdominal pain) or allergy to known composition of inactivated SARS-CoV-2 vaccine;
- History or family history of convulsion, epilepsy, encephalopathy or mental illness;
- Subjects with congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.;
- Subjects with known or suspected diseases include: severe respiratory diseases, severe cardiovascular diseases, severe liver and kidney diseases, drug-uncontrollable hypertension, diabetic complications, malignant tumors, various acute diseases or acute onset of chronic diseases;
- Diagnosed with congenital or acquired immunodeficiency, HIV infection, lymphoma, leukemia or other autoimmune diseases;
- History of coagulation dysfunction (e.g. Coagulation factor deficiency, coagulation disease);
- Subjects receiving anti-TB treatment;
- Subjects receiving other research drugs within 6 months before vaccination;
- Subjects receiving immunotherapy or inhibitor therapy within 3 months (consistently oral or infusion for more than 14 days);
- Subjects receiving blood products within 3 months before administration;
- Subjects vaccinated with live attenuated vaccine within 14 days before vaccination;
- Subjects vaccinated with other vaccine within 7 days before vaccination;
- The researchers shall judge the other conditions which might be not in compliance with the requirements of this clinical trial.
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Forebygging
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Placebo komparator: Placebo
|
2 doser Placebo skal gis som en intramuskulær injeksjon i deltoideus lateral i overarmen med et intervall på 28 dager.
|
Eksperimentell: kandidatvaksine
|
2 doses of SARS-CoV-2 Vaccine (Vero Cells), Inactivated with a 28-day interval constitute a primary immunization course. The third dose on 6 months after primary course is the booster dose. Administer as an intramuscular injection into the lateral deltoid of the upper arm. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Seroconversion rate of SARS-CoV-2 neutralizing antibody
Tidsramme: 28 days post full primary immunization course
|
28 days post full primary immunization course
|
Geometric mean titer of SARS-CoV-2 neutralizing antibody
Tidsramme: 28 days post full primary immunization course
|
28 days post full primary immunization course
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Forekomst av uønskede reaksjoner/hendelser
Tidsramme: 0-28 dager etter hver vaksinasjon
|
0-28 dager etter hver vaksinasjon
|
Serious Adverse Events (SAE)
Tidsramme: within 12 months post full primary immunization course and the booster dose respectively
|
within 12 months post full primary immunization course and the booster dose respectively
|
Seroconversion rate of SARS-CoV-2 IgG binding antibody
Tidsramme: 28 days post full primary immunization course
|
28 days post full primary immunization course
|
Geometric mean titer of SARS-CoV-2 IgG binding antibody
Tidsramme: 28 days, 3 months, 6 months and 12 months post full primary immunization course
|
28 days, 3 months, 6 months and 12 months post full primary immunization course
|
Geometric mean titer of SARS-CoV-2 IgG binding antibody
Tidsramme: 28 days, 3 months, 6 months and 12 months after the booster dose
|
28 days, 3 months, 6 months and 12 months after the booster dose
|
Geometric mean titer of SARS-CoV-2 neutralizing antibody
Tidsramme: 3 months, 6 months and 12 months post full primary immunization course
|
3 months, 6 months and 12 months post full primary immunization course
|
Geometric mean titer of SARS-CoV-2 neutralizing antibody
Tidsramme: 28 days, 3 months, 6 months and 12 months after the booster dose
|
28 days, 3 months, 6 months and 12 months after the booster dose
|
Seropositive rate of SARS-CoV-2 neutralizing antibody
Tidsramme: 3 months, 6 months and 12 months post full primary immunization course
|
3 months, 6 months and 12 months post full primary immunization course
|
Seropositive rate of SARS-CoV-2 neutralizing antibody
Tidsramme: 28 days, 3 months, 6 months and 12 months after the booster dose
|
28 days, 3 months, 6 months and 12 months after the booster dose
|
Seropositive rate of SARS-CoV-2 IgG binding antibody
Tidsramme: 3 months, 6 months and 12 months post full primary immunization course
|
3 months, 6 months and 12 months post full primary immunization course
|
Seropositive rate of SARS-CoV-2 IgG binding antibody
Tidsramme: 28 days, 3 months, 6 months and 12 months after the booster dose
|
28 days, 3 months, 6 months and 12 months after the booster dose
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Forventet)
1. september 2021
Primær fullføring (Forventet)
1. mars 2023
Studiet fullført (Forventet)
1. april 2023
Datoer for studieregistrering
Først innsendt
10. august 2021
Først innsendt som oppfylte QC-kriteriene
10. august 2021
Først lagt ut (Faktiske)
12. august 2021
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
18. august 2021
Siste oppdatering sendt inn som oppfylte QC-kriteriene
11. august 2021
Sist bekreftet
1. august 2021
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 2020L001-2B
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Covid-19
-
Yang I. PachankisAktiv, ikke rekrutterendeCOVID-19 luftveisinfeksjon | COVID-19 stresssyndrom | Covid-19-vaksinebivirkning | COVID-19-assosiert tromboembolisme | COVID-19 Post-Intensive Care Syndrome | COVID-19-assosiert hjerneslagKina
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico og andre samarbeidspartnereFullførtPostakutte følgetilstander av COVID-19 | Tilstand etter covid-19 | Langvarig COVID | Kronisk COVID-19 syndromItalia
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRekrutteringCovid-19-pandemi | Covid-19-vaksiner | COVID-19 virussykdomIndonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkHar ikke rekruttert ennåPost-COVID-19 syndrom | Lang COVID | Lang Covid19 | Tilstand etter covid-19 | Post-COVID syndrom | Tilstand etter COVID-19, uspesifisert | Tilstand etter COVIDNederland
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyFullførtPost-COVID-19 syndrom | Long-COVID-19 syndromTyskland
-
Indonesia UniversityRekrutteringPost-COVID-19 syndrom | Lang COVID | Tilstand etter covid-19 | Post-COVID syndrom | Lang COVID-19Indonesia
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRekrutteringCOVID-19 lungebetennelse | COVID-19 luftveisinfeksjon | Covid-19-pandemi | COVID-19 akutt respiratorisk distress-syndrom | COVID-19-assosiert lungebetennelse | COVID 19 assosiert koagulopati | COVID-19 (Coronavirus Disease 2019) | COVID-19-assosiert tromboembolismeHellas
-
Endourage, LLCRekrutteringLang COVID | Lang Covid19 | Post-akutt COVID-19 | Langdistanse COVID | Langdistanse COVID-19 | Postakutt covid-19 syndromForente stater
-
First Affiliated Hospital Xi'an Jiaotong UniversityShangluo Central Hospital; Ankang Central Hospital; Hanzhong Central Hospital og andre samarbeidspartnereRekrutteringKohortoppfølging av epidemi og nevroimaging for pasienter under den første bølgen av COVID-19 i KinaCovid-19 | Post-COVID-19 syndrom | Post-akutt COVID-19 | Akutt COVID-19Kina
Kliniske studier på Placebo
-
SamA Pharmaceutical Co., LtdUkjentAkutt bronkitt | Akutt øvre luftveisinfeksjonKorea, Republikken
-
National Institute on Drug Abuse (NIDA)FullførtCannabisbrukForente stater
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyFullførtMannlige personer med type II diabetes (T2DM)Tyskland
-
Heptares Therapeutics LimitedFullførtFarmakokinetikk | SikkerhetsproblemerStorbritannia
-
Regado Biosciences, Inc.FullførtFrivillig friskForente stater
-
Texas A&M UniversityNutraboltFullførtGlucose and Insulin Response
-
Longeveron Inc.AvsluttetHypoplastisk venstre hjertesyndromForente stater
-
ItalfarmacoFullførtBecker muskeldystrofiNederland, Italia
-
Instituto de Investigación Hospital Universitario...Creaciones Aromáticas Industriales, S.A. (CARINSA)Fullført